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Abstract 
  We evaluated the performance of a large set of serum biomarkers in the prediction 
of rapid progression of chronic kidney disease in people with type 2 diabetes.  We 
used a case-control design, nested within a prospective cohort of people with 
baseline eGFR 30-60 ml/min/1.73m2.  Cases (n=154) had a >40% eGFR decline 
within 3.5 years of follow-up and controls (n=153) maintained>95% of baseline 
eGFR at end of follow-up.  We measured 207 serum biomarkers and used logistic 
regression with forward selection to select a subset of biomarkers that maximized 
prediction on top of clinical variables including age, sex, HbA1c, eGFR and 
albuminuria.  Nested cross-validation was used to determine the best number of 
biomarkers to retain and to evaluate predictive performance. 30 biomarkers showed 
significant associations with rapid progression (p<0.0003 adjusted for clinical 
characteristics).  A panel of 14 biomarkers increased the area under the ROC curve 
from 0.706 (clinical data alone) to 0.868.  Biomarkers selected included fibroblast 
growth factor-21, symmetric:asymmetric dimethylarginine ratio, beta 2-microglobulin, 
C16-acylcarnitine, and kidney injury molecule-1.  Using more extensive clinical data, 
including pre-baseline eGFR slope improved prediction but to a lesser extent than 
biomarkers (Area under the ROC curve = 0.793).  We report several novel 
associations of biomarkers with Chronic Kidney Disease progression and the utility 
of a sparse panel of biomarkers in improving prediction. 
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Introduction 
Kidney disease is a major cause of morbidity and mortality in patients with type 2 
diabetes. (1)  Developing new therapies to prevent kidney disease incidence and 
progression is a priority with many pharmaceutical companies currently having drugs 
in development.  However, clinical trials in this area are challenging as there is a 
need to demonstrate prevention of progression of renal function decline or 
progression to end stage renal disease (ESRD) over a typical trial time horizon of a 
few years.  Even from stage 3 Chronic Kidney Disease (CKD) the majority of patients 
progress only very slowly over say a five year horizon.  Albuminuria and estimated 
Glomerular Filtration Rate (eGFR) status are currently our best means of identifying 
those at highest subsequent risk of ESRD.  Identifying those at risk of more rapid 
progression would allow risk stratification and improved trial power and efficiency 
and would also enable targeting of new therapies as they become available.   
 
There is considerable interest in developing biomarkers that would help in such 
prediction beyond the commonly used legacy biomarkers serum creatinine, 
albuminuria, and cystatin-C. Many evaluations of single or small sets of candidate 
biomarkers have been reported.(2, 3)  In this study we explored a broad set of 207 
serum protein and metabolite biomarkers, some candidate and some unbiased 
discovery biomarkers in 154 incident cases of rapid progression of renal function 
decline from CKD3 and 153 non-progressing controls from the Genetics of Diabetes 
Audit and Research Tayside Study (GO-DARTS) a Scottish type 2 diabetes cohort.  
Our aim was to identify a subset of biomarkers that together could maximise 
prediction of rapid progression of renal function decline on top of clinical history.  The 
study is part of the Surrogate markers for Micro- and Macro-vascular hard endpoints 
for Innovative diabetes Tools programme, ’SUMMIT’, funded by the Innovative 
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Medicines Initiative.(4)  This is a collaborative endeavour across 19 academic 
centres and 6 pharmaceutical industry partners across Europe to identify novel 
biomarkers for the complications of diabetes in order to reduce bottlenecks in 
diabetes drug development.  The study was designed to be closely aligned to the 
typical trial setting i.e. taking CKD 3 as the baseline state from which to improve 
prediction of further renal function decline.  
 
Results 
Overall 12.5% of the Go-DARTS population with CKD3 at baseline lost >40% of their 
baseline eGFR within 3.5 years and were defined as cases. Follow-up eGFR data 
was available for a median of  5.5 (IQR  3.2, 6.0) years. Baseline demographics for 
the study population are shown in Table 1.  Cases had longer diabetes duration, 
greater prevalence of albuminuria and retinopathy and a lower median eGFR at 
baseline than the controls. 
Data reduction steps 
All 207 biomarkers measured are listed in Online Supplementary Material (OSM) 
Table 1.  From this initial panel we removed forty-two biomarkers from further  
analysis as being uninformative (OSM Table 2), either because very few patients 
had detectable levels of the biomarker (n=22), or the biomarker was in tight 
correlation (r>0.9) with another biomarker (n=15)  or because of too few results due 
to inadequate sample volume analysis (n=5).  This left 165 biomarkers and we also 
evaluated the ratio of symmetric dimethylarginine (SDMA) to asymmetric 
dimethylarginine (ADMA).  Many of the biomarkers measured had very strong 
correlations with each other (OSM Table 3).   
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Univariate associations 
 
The medians by case control status for all 166 biomarkers are shown in OSM Table 
4. The volcano plot (Figure 1) shows the associations with rapid progression for all 
166 biomarkers evaluated singly and adjusted for baseline age, sex, eGFR, 
albuminuria, HbA1c, and ACE Inhibitor and Angiotensin Receptor Blocker (ARB) 
use.  Cystatin-C and beta 2-microglobulin which are strongly correlated (rho =0.82) 
had the strongest associations with similar effect sizes per standard deviate.  We 
retained 62 biomarkers for further evaluation as having at least suggestive evidence 
for association in the initial cross validated logistic regression for each biomarker 
evaluated alone.  Table 2 lists the 30 biomarkers that reached Bonferroni adjusted 
significance level (p<0.0003) on adjustment for clinical covariates, examined singly 
with odds ratios for association with being a case.  
 
Biomarker panel performance 
 
Figure 2a shows the performance on withdrawn data of the biomarker panels 
chosen by the forward selection process with a fixed termination criterion and those 
chosen by a top down selection process that was run with varying sparsity 
constraints i.e. set to terminate at different numbers of retained biomarkers.  The 
Area under the ROC curve (AUROC) for a model including only clinical covariates 
was 0.706 (95% CI: 0.654, 0.772).  The forward selection process selected 14 
biomarkers as contributing to prediction improvement beyond the clinical covariates.  
This yielded a substantial increment in AUROC to 0.868 (95% CI: 0.832, 0.915).  
The difference in log-likelihoods computed on withdrawn data between the two 
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models was 35 natural log units, indicating that the addition of biomarkers 
significantly improved the prediction of the model.  Using the top down approach, 
performance could be improved to varying degrees depending on the number of 
biomarkers selected reaching a maximum AUROC of 0.892 (95% CI: 0.859-0.934), 
but requiring 35 biomarkers to achieve this.  
 
The GO-DARTS dataset contains retrospective clinical data pre-baseline so we 
further examined the contribution of biomarkers to prediction beyond that achieved 
by using an extended set of clinical covariates data including longitudinal eGFR pre-
baseline (see methods for full list).  This extended clinical dataset showed a 
substantially higher prediction than the basic clinical covariate model (AUROC = 
0.793 (95% CI: 0.738, 0.841) vs. 0.706 respectively).  Addition of selected 
biomarkers improved prediction somewhat further with an increment in AUROC to 
0.859 (95% CI: 0.816-0.902) with a panel of 7 biomarkers selected by forward 
selection, and a maximal AUROC of 0.871 (95% CI: 0.834-0.915) achieved with top 
down selection retaining 25 biomarkers (Figure 2b).  
 
Replacing the dichotomous albuminuria variable with a continuous measure of 
urinary albumin concentration for the 220 individuals with data available using a 
single method did not improve the AUROC for either the restricted clinical covariate 
or extended clinical covariate models and the improvement in AUROCs due to the 
addition of biomarkers was of similar degree whether the clinical covariate model 
included the dichotomous or continuous albumin measure  (data not shown).   
 
8 
 
Figure 3a shows the AUROC curves for the forward selection panel of 14 
biomarkers and the top down selection of 35 biomarkers. However, a useful metric 
that summarises the potential value of biomarkers in selection of patients for a 
clinical trial is the “predicted event rate enrichment” achieved by using the biomarker 
panel in a given potential clinical trial population (Figure3b).  For example in the Go-
DARTS cohort just 12.5% of those meeting the eGFR baseline entry criterion of 30-
60ml/min/1.73m2 progressed to being a case within 3.5 years.  Thus, without any 
selection by risk stratification (y axis of Figure 3b= 1) the expected cumulative 
incidence of progression is 12.5% (x-axis).  The plot illustrates that selecting say the 
top 20% (y axis =0.2) of patients based on their score from a model combining 
clinical covariates and selected biomarkers could enrich the cumulative incidence of 
rapid progression to >60%.   
 
Components of the Selected Panels 
The 14 biomarkers selected by forward selection and their association with rapid 
progression adjusted for each other and clinical covariates in a logistic regression 
model are shown in Table 3.  These biomarkers are for the most part a subset of the 
maximally predictive 35 biomarker panel selected by top down regression with the 
exception that cystatin-C was selected with top down, whereas beta-2-microglobulin,   
was selected instead in forward selection.  Also adrenomedullin showed only weak 
association with progression when adjusted for the other biomarkers and was not 
included in the top down selection (see OSM Table 5).  
 
The 7 biomarkers selected in the forward selection panel on top of the extended 
clinical covariates are a subset of the 14 biomarker panel– Kidney Injury Molecule 1 
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(KIM-1), SDMA:ADMA ratio, beta 2-microglobulin, alpha-1 antitrypsin (2), C-16 
acylcarnitine, fibroblast growth factor-21 (FGF-21) and uracil.  
 
Discussion 
In this study of individuals with type 2 diabetes and CKD3 we found that within a 
large set of candidate and global discovery biomarkers, at least 62 showed some 
evidence for association with subsequent rapid renal function decline.  Many of these 
biomarkers showed high correlations with each other and with clinical covariates so 
that a much sparser set of 14 biomarkers contained most of the predictive 
information beyond clinical covariates.  We found that the increment in prediction 
with these biomarkers was of sufficient magnitude that it would be useful for risk 
stratification into clinical trials.  Some of the biomarkers identified in the most 
predictive panels are already known to be associated with eGFR (i.e.beta-2-
microglobulin and cystatin-C), whereas others have little or no prior data (e.g. 
SDMA:ADMA ratio, FGF-21, uracil).  The best biomarker panel for prediction 
consisted of the restricted clinical covariates along with 35 biomarkers; however, this 
was only modestly better than the best sparse model which only required 
measurement of 14 biomarkers.  The expense and logistics associated with 
validation and subsequent utilization of any new panel means that the 14 biomarker 
panel represents a more pragmatic approach.  This panel of biomarkers now 
warrants further evaluation in other cohorts.  
 
We used clinical creatinine measurements to calculate eGFR in this study and as 
there is considerable variability in this measure it is unsurprising that the in-sample 
measure of creatinine was also selected in our biomarker panels.  Space does not 
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permit a detailed discussion of each of the 14 biomarkers selected and some of the 
associations have been described elsewhere.  (5, 6) Here we focus on some of the 
more novel associations.  
 
One of the strongest predictive biomarkers in our study was the ratio of 
SDMA:ADMA. SDMA and ADMA are released during proteolytic breakdown of 
nuclear proteins and both have been studied as biomarkers for cardiovascular 
disease (CVD).(7-9)  SDMA is primarily excreted via the kidney and is strongly 
associated with renal function(7) but there is also some evidence that the protein 
methyltransferase PRMT5 that synthesises SDMA regulates interleukin-2-gene 
expression (10) suggesting that higher levels of SDMA might also reflect 
inflammation.  We did not find any association of SDMA with inflammatory 
biomarkers such as C-reactive protein but there was a positive correlation (rho=0.39) 
with interleukin-2 receptor 1-alpha levels. However rather than a bioactive effect of 
SDMA itself, the observed prediction in our study may simply indicate that SDMA 
accumulates when filtration falls and thus it is predictive because it is a good 
biomarker of filtration.  In contrast to SDMA we found that ADMA was only weakly 
inversely correlated with eGFR but more strongly correlated with arginine.  The ratio 
may be a biomarker of these complex interactions and we note that models including 
the ratio yielded higher AUROCs than models including ADMA and SDMA 
separately. 
 
KIM-1 is a protein expressed on the apical membrane of proximal tubule cells.  Its 
ectodomain is shed into the lumen and serves as a urinary biomarker of kidney injury 
though there have been mixed results for it as a prognostic biomarker in diabetic 
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kidney disease.(11, 12)  Studies have shown that KIM-1 expression is increased in 
the glomerulus in diabetic animal models (13) and is elevated in their plasma.(14)    
Recently, it was reported that shed KIM-1 also serves as a blood biomarker of kidney 
injury in humans, since plasma KIM-1 levels were higher in patients with acute 
kidney injury (AKI) than in healthy controls or post-cardiac surgery patients without 
AKI.(2)  In that study serum KIM-1 level at baseline in type 1 diabetes patients 
strongly predicted rate of eGFR loss and risk of ESRD during 5-15 years of follow-
up.    
 
We identified associations with rapid progression of two fibroblast growth factor 
members -FGF-21 and FGF-23. FGF-21 is a 181 amino acidpolypeptide secreted 
predominantly by the liver and adipose tissue and has been shown to play an 
important role in lipid and energy metabolism.(15, 16)  Previous studies have 
reported cross sectional associations with eGFR. (17)  Median serum FGF-21 levels 
were >7-15-fold higher in dialysis patients than controls (18, 19) but fell after short 
term angiotensin blockade.(19)  In cross sectional studies FGF-21 levels were also  
elevated with albuminuria even when eGFR was >60 ml/min.(20)  FGF-21 was 
independently associated with urinary albumin in type 2 diabetes.(20)  The kidney 
has relatively low levels of FGF-21 (21) and FGF-21 activity depends on the tissue 
specific expression of its co-factor Klotho β, which is predominantly in the liver and 
adipose tissue rather than the kidney.  Thus, association between FGF-21 and renal 
disease progression may reflect simple accumulation in renal disease.  However, it 
might also reflect an anti-fibrotic response; it was shown that FGF-21 prevented the 
expression of pro-fibrotic cytokines, including TGF-β1 in the kidney.(22)  FGF-23 is a 
32-kD bone derived hormone with several known endocrine functions in the kidney, 
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including the promotion of urinary phosphate excretion and the inhibition of the 
hydroxylation of 25-hydroxyvitamin D.(23)  Elevated FGF-23 was an independent 
risk factor for end-stage renal disease in patients with relatively preserved kidney 
function and for mortality across the spectrum of CKD.(24)  Recently it was shown in 
13,448 subjects of the Atherosclerosis Risk in Communities study (ARIC), that higher 
serum level of FGF-23 were associated with increased risk of incident ESRD, 
independent of the baseline level of kidney function and a number of other risk 
factors.(25) 
 
C16-acylcarnitine was one of the strongest predictors of rapid progression in our 
study.  Previously in the KORA cohort acylcarnitines and especially the ratio of 
serine to glutarylcarnitine were associated with eGFR(26) and in FinnDiane urinary 
acylcarnitines were associated with albumin levels.(27)  Higher plasma 
acylcarnitines were also predictive of ESRD in a small study of people with type 1 
diabetes.(28)  We found that C16-acylcarnitine was only weakly inversely correlated 
with eGFR (rho=-0.11) and only modestly associated with cystatin C (rho=0.31) yet 
was strongly associated with rapid progression. 
 
Our study found other novel associations with renal disease progression that warrant 
further investigation including alpha 1 antitrypsin, which has been identified as a 
potential urinary biomarker for renal disease.(29, 30)  We should note this measure 
had 50% of values missing at random, however a sensitivity analysis restricted to 
data without imputation showed the univariate odds ratio for it was essentially 
unchanged (1.77 in the imputed data vs. 1.74 in the unimputed data).  Other 
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biomarkers such as hydroxyproline, creatine, uracil and Fatty Acid Binding Protein 
Heart reported here currently have no direct explanation for the associations. 
 
We also showed that much of the increment in prediction gained with biomarkers 
could be obtained with the use of more extensive historical clinical data.  However, 
typically in clinical trials there is little historical data available. In using this more 
extensive data we did not do any variable selection, instead we fitted a model using 
all the variables available that were likely to be relevant.  There is no consensus on a 
risk prediction model for renal disease progression.  A recent review of risk 
prediction models for patients with CKD revealed limited data with a wide range of 
end points including ESRD, incident CVD, and mortality.(31) Risk prediction models 
for clinical purposes will also become more important as new treatments arise for 
prevention of progression of renal disease in diabetes and biomarkers may be useful 
additions to clinical covariates again where extensive past medical history, including 
historical eGFR measures are not available.   
 
The strengths of this study are that we have measured a large number of biomarkers 
covering numerous pathophysiological pathways.  We have also made use of k-fold 
cross-validation and machine learning methods that avoid the problem of over-fitting 
when testing large numbers of associations and increase the generalisability of 
findings to other settings.  Though further studies of the generalisability of findings 
are warranted.   
 
There are also weaknesses. The sample size is modest and only one cohort has 
been studied and validation in external cohorts is needed. We used a dichotomous 
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variable for albuminuria due to no single method used for all samples to assess 
albuminuria status. As a result there is potential for residual confounding due to 
albuminuria. However, a sensitivity analysis of the sub-group with albumin 
concentration data measured by a single method showed that the increment in 
AUROC achieved by adding biomarkers to the clinical covariates was not reduced by 
the use of a continuous measure of albuminuria rather than the dichotomous 
variable. Thus, we think it is reasonable to conclude that the biomarkers are not 
materially affected by residual confounding. Another weakness is that we only have 
limited data from blinded duplicate samples due to limited volume availability though 
in general the repeatability data was good (see OSM page 4). We also note that the 
effect of errors in measurement act to reduce the power to detect associations rather 
than introduce false positive associations. Thirdly, we did not have a measure of 
every biomarker in every sample which required us to impute missing values. 
However, the degree of missing at random was not high with only 6 biomarkers in 
the study having ≥30% of values imputed and a sensitivity analysis examining 
individual biomarker associations after adjustment for clinical covariates in the non-
imputed data showed consistent associations with those seen in the imputed 
dataset.  
 
In keeping with our aim to identify biomarkers that might improve clinical trial 
stratification we have restricted the study to individuals with CKD3 at baseline.  It is 
not possible to conclude that biomarkers that are associated with progression at this 
stage will also be predictive of progression in individuals with CKD1 or 2 and studies 
are needed to examine biomarkers in such individuals.  It should also be noted that 
panels of biomarkers predicting from earlier stages of renal disease are more likely 
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to include biomarkers that are in the causal pathway whereas panels predicting from 
CKD3 may include biomarkers altered secondarily due to declines in glomerular 
filtration.  The study also does not identify biomarkers that are necessarily specific 
for renal decline due to diabetic kidney disease as the underlying cause of renal 
disease in people with type 2 diabetes is highly heterogeneous. (32)  
 
In conclusion we identified a panel of biomarkers that substantially improved the 
prediction of rapid progression of renal decline in people with diabetes and identified 
novel associations of biomarkers that warrant further investigation for relevance to 
pathogenesis of kidney disease in type 2 diabetes.   
 
Methods 
Data and Sample Sources 
All samples for this study came from the Go-DARTS cohort. Go-DARTS is a hospital 
clinic and primary care based sample of people diagnosed with type 2 diabetes in 
the Tayside region of Scotland.  Adults attending primary and secondary care in the 
area were invited to participate and enrolled in the study between December 1998 
and May 2009 and are continuously followed up using linked electronic health care 
data.(33)   The final sample comprises ~75% of all those with type 2 diabetes 
residing in Tayside.  Diabetes status was based on a clinical record of a diagnosis of 
diabetes and was validated by checking against the clinical record data, on-going 
prescription and biochemistry laboratory data for results in keeping with the presence 
of diabetes.  Patients gave a blood sample at study entry and agreed to have their 
routine and diabetes specific clinical and mortality records ascertained prospectively.  
Covariate data including prescription information, blood pressure and anthropometry 
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results were obtained by extraction from the ongoing primary care and hospital 
diabetes electronic records.  Laboratory data is supplied directly to the Go-DARTS 
database so we have access to all serum creatinine values measured as part of 
routine clinical practice both before and after study enrollment. 90% of study 
participants had ≥1 eGFR measure per year of available follow-up.  The study 
complied with the Declaration of Helsinki guidelines and informed consent was 
obtained from all study participants. 
 
Rapid Progressor Phenotype 
The phenotype for this study was designed around the typical enrolment criteria into 
trials for assessing reno-protective drugs.  We identified all individuals with CKD3 
(i.e. an eGFR of 30-60ml/min/1.73m2) at enrolment.  People were classified as cases 
if they lost >40% of their baseline eGFR within 3.5 years of follow-up and as controls 
if their most recent eGFR measure was >95% of baseline after follow-up of >3.5 
years and had no fall in eGFR to <80% of baseline at any time during follow-up.  
Individuals were excluded if they had not received anti-hypertensive treatment within 
1 year of baseline (to eliminate people not receiving active management) or had a 
history of hospital admission for acute renal failure (as assessed by hospital 
admission data) during follow-up. EGFR was calculated using the serum creatinine 
measured at the clinical laboratory (principally measured with alkaline picrate based 
methods) using the MDRD4 equation eGFR = 186 x (creatinine in mmol/l/88.4)-1.154 x 
(age-0.203) x 0.742 (if female)x (1.210 if black).(34) 
 
Biomarker Measurements 
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Biomarkers were selected either on the basis of hypothesis-driven rationale (i.e. 
published biomarkers from relevant pathophysiological pathways such as kidney 
function, tubular intestinal injury, glomerular injury, endothelial dysfunction, oxidative 
stress, inflammation, fibrosis, cardiovascular dysfunction, metabolic disorders) or 
hypothesis-free as part of global discovery.  
We used three platforms; 1) ELISA kits were used to measure 5 candidates at the 
University Heart Center Hamburg biomarker laboratory 2) Luminex technology was 
used to perform multiplexed, microsphere-based assays for 58 biomarkers by 
combining optical classification schemes, biochemical assays, flow cytometry and 
advanced digital signal processing as described (35) at the CLIA certified Myriad 
RBM laboratory (Austin TX, USA).  Some of the biomarkers measured on this 
platform were selected specifically due to high interest for example KIM-1, Cystatin-
C, while others were included due to being plexed with biomarkers of high interest 
for example beta-amyloid 42); and 3) liquid chromatography (LC) electrospray 
tandem mass spectrometry (MSMS) platforms for targeted metabolite and tryptic 
peptide analyses were used to yield quantitation of 144 metabolites and peptides at 
the WellChild Laboratory (Kings College London, UK).  Here we made use of the 
extensive biomarker platform that has been developed, to measure biomarkers in 
which we had specific interest (e.g SDMA, NAG) and at the same time acquire data 
on a broader set of metabolites and tryyptic peptides dereived from plasma proteins 
for which we had no prior evidence.  Further details of methods and sample quality 
control data for the 207 biomarkers measured is given in the OSM methods section 
and OSM table 1.     
 
Clinical Covariates 
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Clinical covariates were recorded at the study day visit and included Body Mass 
Index (BMI) and blood pressure (the average of two readings). HbA1c and serum 
creatinine were measured on the day of sampling as part of routine clinical testing by 
standard clinical laboratory methods.  Albuminuria was assessed by either a urinary 
albumin concentration on a spot urine or a 24hour urinary protein concentration with 
evidence of albuminuria based on the highest level of albuminuria (normo, micro or 
macroalbuminuria) recorded in the 5 years prior to baseline.  Smoking status was 
based on patient report at study enrolment.  Prior CVD was based on the presence 
of an ICD-9 or ICD-10 code consistent with a major CVD event prior to sampling.  
Medication was based on primary care prescribing data at study enrolment.  
Retinopathy status was derived from the retinal screening examination grade closest 
to study enrolment.  We used all measures of serum creatinine up to the time of 
sampling to calculate a weighted historical eGFR with greatest weight given to the 
more recent measures.  For analysis we considered a basic set of clinical covariates 
(age, sex, eGFR, albuminuria, HbA1c, ACE Inhibitor use and ARB use) as well as an 
extensive set which also included blood pressure, the weighted average of past 
eGFRs over a median of 7.2 years, diabetes duration, BMI, prior CVD, insulin use 
and use of antihypertensive drugs. 
Data cleaning and imputation 
The data from the biomarker laboratories was cleaned and imputed before analysis. 
We used a sparse iterative regression model for imputation (see OSM methods).  
We used imputation for two issues: left censoring i.e. values below detection limit 
and for completely missing at random values.  All data were Gaussianized prior to 
analysis  
Data analysis 
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We applied two complementary approaches to biomarker selection: forward 
selection using logistic regression, and sparse logistic regression with the L1 
(LASSO) regularization penalty (36) (see OSM methods).  Prior to selection models 
we included two filter steps: step one identified all biomarkers with a correlation of 
>0.9 and for each pair retained a single biomarker (see OSM table 2)- where one of 
the pair of biomarkers was of high prior interest we selected it over the non-high prior 
interest biomarker (this was the case with the retention of N-Terminal Prohormone B 
type Natriuretic Peptide over Malondialdehyde-Modified Low-Density Lipoprotein), 
but otherwise the choice of which biomarker in the pair to retain was random; and 
step two used the training set data to identify biomarkers with univariate association 
with the outcome and selected the 50 biomarkers with the strongest associations.  
We assessed prediction in models where we included or omitted this second filtering 
step and showed that the best performance was seen with the filtered models.  
 
  We used nested k-fold cross validation for learning the parameters of the selection 
models and actually performing the selection of the biomarker panels.  This learning 
was done on the training fold data (and inner folds defined within it), while the test 
fold is reserved exclusively for testing the performance of the biomarker panel by 
computing AUROCs.  By only testing the performance on test data not used for 
selection this yields an unbiased estimate of the AUROC.  We used the AUROC on 
test data as the performance criterion.  The highest-scoring method was re-applied 
to select the final biomarker panel using the complete dataset, and summary 
statistics of the resulting biomarkers were reported.  We used difference in log 
likelihood computed on withdrawn data to determine whether there was a significant 
difference between pairs of models using a threshold of a difference of 1 natural log 
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units as a cut point for statistical significance (see OSM page 4).  We also calculated 
the positive predictive value of the test where the probability of a case being correctly 
identified as such is plotted against the percentile of the score, to demonstrate how 
using different cut points of the model score might alter probability of identifying 
those at risk for progression.  
 
All data preparation and analyses were performed using R version 2.15.2. 
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Figure Legends 
Figure 1: Volcano Plot of Association of 166 Biomarkers with Rapid 
Progression of eGFR decline  
The labelled points are where there was a level of significance -log10(pvalue) >9 or a 
fold-change greater than +/- >0.6.  
Figure 2: Performance Metrics of Models by Number of Biomarkers Retained 
and Selection Method  
Model performance plots showing the AUROC achieved with the forward selection 
panel (shown by filled blue square) compared with the performance of the top down 
selected panels (shown by yellow diamonds) with the number of retained biomarkers 
allowed to vary up to 35 biomarkers. 
A) On top of the AUROC achieved by age, sex, HbA1c, albuminuria, eGFR. ACE 
Inhibitor and Angiotensin Receptor Blocker use alone 
B) On top of the AUROC achieved by an extended set of clinical covariates 
including longitudinal eGFR (see methods for full list) 
Figure 3: Performance of Panels of Biomarkers Chosen by Forward Selection 
and Top Down Selection Compared with Clinical Data Alone 
Performance plots for the best overall and sparse biomarker models including clinical 
covariates age, sex, HbA1c, albuminuria, eGFR and ACE Inhibitor and Angiotensin 
Receptor Blocker use (red line), clinical covariates and forward selection biomarkers 
(blue line) and clinical covariates and 35 biomarker panel (yellow line) 
A) Area Under the ROC curves  
B) Positive Predictive Value Plot 
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Table 1: Baseline demographics for cases and controls 
 Control Case 
 Frequency/ 
Median 
Interquartile 
Range 
Frequency/ 
Median 
Interquartile 
Range 
Female sex (%) 64.3 - 57.5 - 
Age (years) 72 66, 76 74 69, 80 
Diabetes Duration (years) 7.2 3.5, 11.0 9.1 5.1, 15.4 
Body Mass Index (kg/m
2
) 29.5 26.1, 34.4 30.6 27.1, 34.8 
Systolic Blood Pressure (mmHg) 144.3 129.8, 153.4 144.0 131.0, 158.5 
Diastolic Blood Pressure (mmHg) 73.3 66.5, 79.4 71.0 63.5, 78.0 
HbA1c (%) 7.1 6.4, 8.2 7.3 6.5, 8.4 
Baseline eGFR (ml/min/1.73m
2
) 51.3 44.9, 54.6 48.2 40.5, 54.8 
Weighted Average eGFR 
(ml/min/1.73m
2
) 
57.8 52.6, 63.5 50.7 44.8, 56.7 
Insulin Use (%) 25.3 - 30.7 - 
Antihypertensive Use (%) 95.5 - 96.1 - 
Diabetic Retinopathy (%) 55.2 - 74.5 - 
Smoking (%) 
      Current smoking  
Ex smoker 
      Never smoker 
 
11.7 
40.3 
48.1 
 
- 
- 
- 
 
11.1 
58.2 
30.7 
 
- 
- 
- 
Prior CVD (%) 21.43 - 28.1 - 
Albuminuria * (%) 18.8 - 45.1 - 
Median follow-up (years) 5.8 5.5, 6.2 3.2 2.2, 5.7 
Median time to caseness (years) - - 1.8 1.2, 2.3 
* Albuminuria status relates to the presence of microalbuminuria or macroalbuminuria at the 
time of sampling or any time in the prior 5 years. 
Data was complete except for: BMI missing for 2 people, SBP missing for 3 people, DBP 
missing for 2 people, HbA1c missing for 1 person, and drug treatment missing for 1 person. 
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Table 2: Thirty Biomarkers Significantly Associated with Rapid Progressionof eGFR Examined Singly and Adjusted for Clinical 
Covariates.  
 
Control 
Median 
Control 
IQR 
Case 
Median 
Case 
 IQR OR 95% CI p.value 
Adrenomedullin (ng/ml) 2.2 1.7, 2.6 2.9 2.4, 3.6 2.94 2.10, 4.22 <0.00001 
Alpha-1 Antitrypsin (2) 161.37 127.79, 187.81 186.38 165.60, 214.51 1.77 1.36, 2.33 <0.00001 
Alpha-1-Microglobulin (ug/ml) 17.0 14.0, 20.0 21.0 19.0, 24.3 3.31 2.31, 4.88 <0.00001 
Beta-2-Microglobulin (ug/ml) 2.0 1.7, 2.4 2.7 2.4, 3.4 6.11 3.90, 10.05 <0.00001 
C16-acylcarnitine (nM/l) 284.14 227.66, 355.38 305.26 280.32, 395.84 1.68 1.29, 2.21 0.00015 
Creatinine (uM/l) 98.18 80.49, 112.60 113.1 91.16, 127.90 3.43 1.97, 6.36 <0.00001 
Cystatin-C (ng/ml) 1340 1140, 1510 1680 1490, 1900 6.34 3.88, 10.97 <0.00001 
Fibroblast Growth Factor 21 (ng/ml) 0.25 0.16, 0.43 0.40 0.30, 0.65 2.06 1.56, 2.80 <0.00001 
Fibroblast growth factor 23 (ng/ml) 0.08 0.05, 0.13 0.12 0.08, 0.22 1.85 1.37, 2.55 <0.00001 
Growth Derived Factor 15 (pg/ml) 2328 1761, 3355 3785 2681, 5555 2.30 1.69, 3.20 <0.00001 
High Sensitivity Troponin T  (pg/ml) 5.29 2.89, 12.89 16.53 9.78, 26.75 3.15 2.11, 4.85 <0.00001 
Interleukin-2 receptor alpha (pg/ml) 2493 2075, 3152 3174 2710, 4180 2.45 1.79, 3.43 <0.00001 
Kidney Injury Molecule-1 (ng/ml) 0.05 0.04, 0.08 0.09 0.07, 0.16 2.60 1.88, 3.68 <0.00001 
Lysine (uM/l) 217.67 190.63, 244.12 203.9 174.87, 215.00 0.55 0.42, 0.72 <0.00001 
Methylmalonic acid (nM/l) 270 220, 350 366 310, 460 2.09 1.56, 2.87 <0.00001 
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Control 
Median 
Control 
IQR 
Case 
Median 
Case 
 IQR OR 95% CI p.value 
N-acetylaspartate (nM/l) 296.58 239.50, 378.61 341.62 306.09, 452.19 1.76 1.33, 2.37 0.00013 
N-terminal prohormone of brain natriuretic 
peptide (pg/ml) 
552.5 247.00, 1152.50 1487.23 607.00, 3170.00 2.10 1.54, 2.94 
<0.00001 
Osteopontin (ng/ml) 15 11, 23 26 18, 33 2.58 1.82, 3.78 <0.00001 
Sialic acid (uM/l) 1.09 0.93, 1.31 1.37 1.19, 1.76 2.43 1.73, 3.52 <0.00001 
Symmetric Dimethylarginine (nM/l) 564 499.00, 647.50 662.91 578.00, 786.00 2.49 1.72, 3.69 <0.00001 
SDMA:ADMA 1.06 (0.93, 1.22) 1.23 1.13, 1.49 2.63 1.86, 3.81 <0.00001 
Tamm-Horsfall Urinary Glycoprotein (ug/ml) 0.04 0.03, 0.05 0.03 0.02, 0.03 0.46 0.33, 0.62 <0.00001 
Thrombomodulin (ng/ml) 5.39 4.60, 6.40 6.5 5.75, 7.40 2.00 1.48, 2.73 <0.00001 
Tissue Inhibitor of Metalloproteinases 1 
(ng/ml) 
170 150, 192 188 172, 218 2.02 1.52, 2.74 
<0.00001 
Trefoil Factor 3 (ug/ml) 0.17 0.13, 0.22 0.27 0.21, 0.37 4.17 2.81, 6.42 <0.00001 
Tryptophan (uM/l) 57.31 50.65, 64.25 52.21 43.10, 56.76 0.54 0.41, 0.72 <0.00001 
Tumor Necrosis Factor Receptor I (pg/ml) 2639 1985, 3217 3440 2852, 4130 2.41 1.76, 3.37 <0.00001 
Tumor Necrosis Factor Receptor 2 (ng/ml) 9.7 8.30, 12.00 13 10.00, 16.00 2.55 1.84, 3.63 <0.00001 
Uracil (nM/l) 119.26 94.25, 152.80 136.54 121.23, 172.55 1.76 1.35, 2.35 <0.00001 
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Control 
Median 
Control 
IQR 
Case 
Median 
Case 
 IQR OR 95% CI p.value 
Vascular Cell Adhesion Molecule-1 (ng/ml) 603 530, 747 724 612, 885 1.77 1.34, 2.36 <0.00001 
Odds ratios (OR) are per standard deviate.  
Clinical covariates adjusted for were: age, sex, baseline eGFR, Albuminuria status, HbA1c, use of ACE inhibitors and use of ARBs
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Table 3:  Association of 14 Biomarkers Contributing to Prediction of Rapid 
Progression in Forward Selection Adjusted for Each Other and Clinical 
Covariates* 
 
Odds 
Ratio per 
Standard 
Deviate 
95% Confidence 
Interval P-value 
Symmetric Dimethylarginine : 
Asymmetric Dimethylarginine 
8.36 3.83, 20.40 <0.0001 
Creatinine 3.52 1.54, 8.76 0.0042 
Beta-2-Microglobulin 3.19 1.56, 6.84 0.0019 
Symmetric Dimethylarginine 0.32 0.13, 0.72 0.0075 
Alpha-1 Antitrypsin (2) 2.05 1.38, 3.14 0.0006 
Kidney Injury Molecule-1 1.93 1.18, 3.27 0.0111 
Uracil 1.84 1.22, 2.84 0.0046 
N-terminal prohormone of brain 
natriuretic peptide 
1.84 1.15, 3.01 0.0123 
C16-acylcarnitine 1.76 1.16, 2.73 0.0090 
Hydroxyproline† 1.73 1.12, 2.72 0.0151 
Fibroblast Growth Factor 21 1.69 1.06, 2.75 0.0288 
Fatty Acid-Binding Protein heart † 0.63 0.38, 1.02 0.0588 
Creatine† 0.65 0.41, 1.01 0.0590 
Adrenomedullin 1.07 0.56, 2.04 0.8370 
*Clinical covariates included: age, sex, baseline eGFR, Albuminuria status, HbA1c, 
and use of ACE Inhibitors or Angiotensin Receptor Blockers† biomarker not 
statistically significant in univariate analyses adjusted only for clinical covariates 
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